TCGA-EW-A1IX-01A-12R-A144-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 40
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.500
- UV_RESPONSE_DN+0.450
- TGF_BETA_SIGNALING+0.440
- ESTROGEN_RESPONSE_EARLY+0.370
- HEDGEHOG_SIGNALING+0.360
- APICAL_JUNCTION+0.310
- ANGIOGENESIS+0.270
- APICAL_SURFACE+0.220
- MYOGENESIS+0.220
- KRAS_SIGNALING_UP+0.200
Top 10 suppressed
- E2F_TARGETS-0.670
- MYC_TARGETS_V1-0.660
- MYC_TARGETS_V2-0.620
- G2M_CHECKPOINT-0.590
- OXIDATIVE_PHOSPHORYLATION-0.530
- INTERFERON_ALPHA_RESPONSE-0.460
- MTORC1_SIGNALING-0.450
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.420
- DNA_REPAIR-0.400
- UNFOLDED_PROTEIN_RESPONSE-0.340
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-E2-A1IO-01A-11R-A144-07 | — | A | 0.929 |
| 2 | TCGA-AR-A2LM-01A-11R-A180-07 | — | A | 0.928 |
| 3 | SRR8613732 | — | A | 0.927 |
| 4 | TCGA-HN-A2OB-01A-21R-A27Q-07 | — | A | 0.916 |
| 5 | TCGA-DK-A3IQ-01A-31R-A32Y-07 | — | — | 0.916 |
| 6 | f65f4ed5-9726-4eff-8638-63752686d2c9 | — | — | 0.915 |
| 7 | SRR11296795 | — | — | 0.912 |
| 8 | TCGA-E9-A1NH-01A-11R-A14D-07 | — | A | 0.909 |
| 9 | TCGA-CR-6488-01A-12R-2081-07 | — | — | 0.907 |
| 10 | s0122297 | — | — | 0.905 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.500 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.450 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.440 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.370 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.360 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.310 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.270 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.220 | Temsirolimus | — uncovered |
| MYOGENESIS | 0.220 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.200 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.190 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.150 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.150 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.140 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.140 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.120 | Inavolisib | — uncovered |
| APOPTOSIS | 0.110 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.060 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.050 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.050 | Remibrutinib | — uncovered |